Our sister site, Drug Delivery Business News, reports today that the San Diego-based continuous glucose monitor maker invested $75 million in Oura, maker of the Oura Ring, a smart ring that delivers vital sign, sleep, stress, heart health and activity data.
Dexcom and Oura hope to integrate their technologies, delivering glucose data with biometrics to provide a more complete picture of overall health to users. Additionally, the companies intend to co-market and cross-sell each others’ products. They expect the first app integration to launch in the first half of 2025.
Dexcom continues to offer its leading CGM systems, along with Stelo, its recently launched over-the-counter glucose biosensor. Combining its OTC CGM offering with the retail-available Oura Ring further extends its reach beyond its prescription base.
Get the full story at our sister site, Drug Delivery Business News.
